Aurora Cannabis Inc. (TSE:ACB) has received a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is C$11.21.
Several brokerages recently weighed in on ACB. ATB Capital raised their price target on shares of Aurora Cannabis from C$10.50 to C$13.00 and gave the company a “sector perform” rating in a research report on Friday, February 12th. Royal Bank of Canada cut shares of Aurora Cannabis to an “underperform” rating in a research report on Tuesday. Canaccord Genuity raised their price target on shares of Aurora Cannabis from C$11.00 to C$14.00 in a research report on Friday, February 12th. MKM Partners reissued a “sell” rating on shares of Aurora Cannabis in a research report on Friday, February 12th. Finally, Stifel Nicolaus lifted their target price on shares of Aurora Cannabis from C$6.50 to C$7.80 in a research report on Friday, February 12th.
In other news, Director Michael Singer sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, February 19th. The shares were sold at an average price of C$15.58, for a total transaction of C$389,500.00. Following the completion of the sale, the director now owns 1,777 shares in the company, valued at approximately C$27,685.66.
Aurora Cannabis (TSE:ACB) last announced its quarterly earnings results on Thursday, February 11th. The company reported C($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.23) by C($0.13). The company had revenue of C$67.67 million for the quarter, compared to analyst estimates of C$69.12 million. Research analysts anticipate that Aurora Cannabis will post -0.62 EPS for the current fiscal year.
Aurora Cannabis Company Profile
Aurora Cannabis Inc produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility engineering and design, cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Further Reading: What is a blue-chip stock?
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.